JNJ
Johnson & Johnson · Healthcare · Drug Manufacturers - General
Momentum-Eingaben (vergleichbare Manager):
Halterbreite -4.3% ·
Aktienfluss -3.3% ·
neue Nettopositionen -4.5%
— Formel
Breite Distribution — sinkende Anteile und weniger Halter
Alle Eigentumszahlen: nur beobachtete 13F-Manager, Stammaktienpositionen, Berichtszeitraum Q1 2025
| Quartal | Inhaber | Δ | Aktien | Gemeldeter Wert | Neu | Ausstiege |
|---|---|---|---|---|---|---|
| Q2 2026 | 183 | +1 | 1.45B | $367.13B | +5 | −3 |
| Q1 2026 | 184 | 0 | 1.43B | $348.29B | +4 | −5 |
| Q4 2025 | 183 | 0 | 1.52B | $314.40B | +2 | −1 |
| Q3 2025 | 28 | 0 | 887.20M | $164.46B | — | −1 |
| Q2 2025 | 26 | +1 | 740.96M | $113.15B | +1 | — |
| Q1 2025 | 22 | -1 | 281.15M | $46.60B | — | −1 |
| Q4 2024 | 23 | +3 | 290.64M | $42.01B | +3 | — |
| Q3 2024 | 19 | -2 | 157.55M | $25.50B | — | −2 |
| Q2 2024 | 21 | — | 161.11M | $23.53B | — | — |
| # | Manager | Aktien | Δ Anteile | Wert | Deren Gewichtung | Gehalten | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passiv) | 133.79M | -0.5% | $22.19B | 0.9% | ▼ Trim | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passiv) | 59.38M | +3.0% | $9.83B | 0.8% | ▲ Add | 4 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passiv) | 59.38M | +3.0% | $9.83B | 0.8% | ▲ Add | 4 | SEC ↗ |
| 4 | Norges Bank ✦ (passiv) | 30.81M | +1.5% | $5.11B | 0.7% | ▲ Add | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 22.65M | -7.0% | $3.76B | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 22.65M | -7.0% | $3.76B | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 22.65M | -7.0% | $3.76B | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 22.65M | -7.0% | $3.76B | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 9 | Wellington Management ✦ | 22.65M | -7.0% | $3.76B | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 10 | Wellington Management ✦ | 22.65M | -7.0% | $3.76B | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 11 | Wellington Management ✦ | 22.65M | -7.0% | $3.76B | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 12 | Wellington Management ✦ | 22.65M | -7.0% | $3.76B | 0.7% | ▼ Trim | 4 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 10.11M | -37.9% | $1.68B | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 10.11M | -37.9% | $1.68B | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 15 | Fisher Asset Management ✦ | 8.71M | +6.3% | $1.44B | 0.6% | ▲ Add | 4 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 5.27M | +51.6% | $873.27M | 0.9% | ▲ Add | 4 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 5.27M | +51.6% | $873.27M | 0.9% | ▲ Add | 4 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 5.27M | +51.6% | $873.27M | 0.9% | ▲ Add | 4 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 5.27M | +51.6% | $873.27M | 0.9% | ▲ Add | 4 | SEC ↗ |
| 20 | AQR Capital Management ✦ | 5.27M | +51.6% | $873.27M | 0.9% | ▲ Add | 4 | SEC ↗ |
| 21 | AQR Capital Management ✦ | 5.27M | +51.6% | $873.27M | 0.9% | ▲ Add | 4 | SEC ↗ |
| 22 | AQR Capital Management ✦ | 5.27M | +51.6% | $873.27M | 0.9% | ▲ Add | 4 | SEC ↗ |
| 23 | Arrowstreet Capital ✦ | 3.30M | +39.5% | $547.50M | 0.4% | ▲ Add | 4 | SEC ↗ |
| 24 | Adage Capital Partners ✦ | 1.28M | +36.8% | $212.01M | 0.4% | ▲ Add | 4 | SEC ↗ |
| 25 | Millennium Management ✦ | 1.25M | -28.2% | $207.97M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 26 | D. E. Shaw & Co. ✦ | 1.17M | +20.8% | $194.69M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 27 | D. E. Shaw & Co. ✦ | 1.17M | +20.8% | $194.69M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 28 | Marshall Wace ✦ | 912.88K | -77.5% | $151.39M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 29 | Marshall Wace ✦ | 912.88K | -77.5% | $151.39M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 30 | Marshall Wace ✦ | 912.88K | -77.5% | $151.39M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 31 | Citadel Advisors ✦ | 664.02K | -64.4% | $110.12M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 32 | Citadel Advisors ✦ | 664.02K | -64.4% | $110.12M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 33 | Markel Group ✦ | 610.80K | 0.0% | $101.30M | 0.9% | Held | 4 | SEC ↗ |
| 34 | Markel Group ✦ | 610.80K | 0.0% | $101.30M | 0.9% | Held | 4 | SEC ↗ |
| 35 | Tweedy, Browne ✦ | 438.27K | -59.4% | $72.68M | 6.4% | ▼ Trim | 4 | SEC ↗ |
| 36 | Bridgewater Associates ✦ | 297.29K | -44.7% | $49.30M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 37 | Renaissance Technologies ✦ | 202.56K | -78.0% | $33.59M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 38 | Gotham Asset Management ✦ | 98.43K | -50.6% | $16.32M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 39 | GAMCO Investors ✦ | 86.71K | -6.7% | $14.38M | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 40 | Fairfax Financial ✦ | 73.40K | 0.0% | $12.18M | 0.7% | Held | 4 | SEC ↗ |
| 41 | Two Sigma Investments ✦ | 23.96K | -62.4% | $3.97M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 42 | Dodge & Cox ✦ | 21.10K | 0.0% | $3.50M | 0.0% | Held | 4 | SEC ↗ |
„Ihre Gewichtung" = Anteil der Position am gemeldeten 13F-Eigenkapitalwert des jeweiligen Managers — das Conviction-Maß. ✦ = kuratorisch ausgewählter Manager.
Neue Käufer
| Keine neu erfassten Käufer in diesem Quartal. |
Ausgestiegen
| Point72 Asset Management | $44.21M | war 0.1% |
Marktweiter Kontext: über ALLE 13F-Melder (strukturierte SEC-Daten, Q1 2026): 1 Inhaber, 136.10K Anteile, $33,268 gemeldet. Dies ist ein anderer, älterer Zeitraum als die oben genannten Zahlen des erfassten Universums; beide werden niemals vermischt.
Was die erfassten Halter dieses Wertpapiers am häufigsten sonst noch halten — Zählungen gemeinsamer Eigentümerschaft, keine fundamentalen Zusammenhänge.
Käufe auf dem offenen Markt (P)
Keine Insider-Käufe auf dem offenen Markt in unserem Erfassungszeitraum.
Verkäufe auf dem offenen Markt (S)
Officer · 15.00K Ant. · $3.95M
Officer, Director · 20.98K Ant. · $5.50M
Officer, Director · 102.31K Ant. · $26.70M
Zuteilungen, Ausübungen und Steuereinbehalte werden hier nie als Käufe oder Verkäufe gezählt. Methodik
The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug to treat a…
Reuters